Physician profile
Himani Singh
NPI 1558546192
$5,128.08
in general payments reported to CMS, 2019-2025
52 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $136 · 2021: $543 · 2022: $806 · 2023: $430 · 2024: $1,038 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.39 |
| Education | $238.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $366.18 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $314.60 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $310.96 | 2019-2024 | Enhertu |
| Daiichi Sankyo INC. | $284.16 | 2020-2025 | Enhertu, Injectafer |
| Seagen INC. | $274.43 | 2019-2023 | Tukysa |
| Novartis Pharmaceuticals Corporation | $261.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $200.48 | 2021-2025 | Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $180.85 | 2019-2024 | Opdualag |
| Celgene Corporation | $179.12 | 2019-2025 | Reblozyl |
| Puma Biotechnology, INC. | $178.56 | 2019-2025 | |
| Sobi, INC | $174.31 | 2023-2025 | |
| Beigene USA, INC. | $164.27 | 2022-2024 | Brukinsa |
| Astellas Pharma US INC | $155.87 | 2019-2025 | Padcev, Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $145.46 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $138.46 | 2021-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Himani Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.